Business
Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will
About this update from Personalis, Inc.
[{"type":"text","content":" MENLO PARK, Calif.--(BUSINESS WIRE)--\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place in Boston, MA, November 17-20, including poster presentations on November 18th and 19th.\n\n\nThe company will showcase ImmunoID NeXT™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.\n\n\nFollowing is a list of abstracts that will be presented at the meeting.\n\n\nScientific Poster Presentations\n\n\n\n\nPoster Number \n\n\n \n\nTitle & Presenter\n\n\n \n\nDay & Time\n\n\n \n\nLocation\n\n\n\n\n\nA19\n\n\n \n\n\n \n\nHLA allele-specific loss of heterozygosity detection\nusing augmented exome capture approach\n\nPresenter: Rachel Marty Pyke, Ph.D.\n\n\n \n\nNovember 18:\n12:30 PM – 3:00 PM\n\n\n \n\nBack Bay\n\n\n\n\n\nB18\n\n\n \n\n\n \n\nExome scale liquid biopsy monitoring of putative\nneoantigens and genomic biomarkers in patients\non anti-PD-1 therapy in squamous cell carcinoma of\nthe head and neck\n\nPresenter: Charles Abbott, Ph.D.\n\n\n \n\nNovember 19:\n4:30 PM – 7:00 PM\n\n\n \n\nBack Bay\n\n\n\n\n\nPersonalis will also be exhibiting during the conference (Exhibit # 10). Representatives will be available to answer questions about the company’s cancer immunogenomics services.\n\n\nAbout Personalis, Inc. \n\n\nPersonalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clin...